pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Approved · small molecule · Pouchitis
Vedolizumab (ENTYVIO) is an approved integrin antagonist developed by Takeda Pharmaceuticals for the treatment of pouchitis, an inflammatory condition affecting patients with a surgically created pouch (ileal pouch-anal anastomosis). The program, identified as Vedolizumab-4004, represents a clinical application of Take
Internal code Vedolizumab-4004
Vedolizumab (ENTYVIO) is an approved integrin antagonist developed by Takeda Pharmaceuticals for the treatment of pouchitis, an inflammatory condition affecting patients with a surgically created pouch (ileal pouch-anal anastomosis). The program, identified as Vedolizumab-4004, represents a clinical application of Takeda's established vedolizumab platform, which has demonstrated efficacy in inflammatory bowel disease. The drug is administered via injection and has completed clinical development with a latest milestone recorded on 24 February 2022. Vedolizumab has achieved regulatory approval in multiple jurisdictions including Australia (first listed 1 August 2015, with subsequent listings through 2024), the European Union (authorised 15 January 2026), and the United States (BLA approvals BLA125476, BLA761133, BLA761359). The program's completion status indicates that pivotal trial data have been generated and regulatory pathways have been navigated. Takeda's strategy appears focused on expanding the therapeutic utility of its vedolizumab franchise beyond its primary inflammatory bowel disease indications into the secondary pouchitis market, where unmet medical need remains significant.
Pouchitis represents a clinically significant unmet medical need affecting a subset of patients who have undergone ileal pouch-anal anastomosis surgery, typically following total proctocolectomy for ulcerative colitis or familial adenomatous polyposis. The condition causes inflammation of the surgically created pouch and can substantially impair quality of life through chronic diarrhoea, urgency, and systemic symptoms. Current treatment options are limited and often include antibiotics (rifaximin, metronidazole, ciprofloxacin) and non-specific anti-inflammatory approaches, with variable efficacy and tolerability concerns. Vedolizumab's mechanism—selective inhibition of α4β7 integrin—offers a mechanistically distinct approach targeting gut-homing lymphocytes, potentially providing superior efficacy and durability compared to traditional antimicrobial or broad-spectrum anti-inflammatory strategies. The patient population, while smaller than primary inflammatory bowel disease cohorts, represents a high-need group with limited pharmacological options. Vedolizumab's approval in pouchitis expands Takeda's addressable market within gastroenterology and reinforces the company's position in integrin-targeted therapeutics. Competitive alternatives remain limited, with most pouchitis management relying on off-label use of systemic agents or antimicrobials, creating a meaningful commercial opportunity for a targeted, mechanism-based therapy.
Drug Class: Integrin antagonist (selective α4β7 inhibitor)
Modality: Small molecule
Route of Administration: Injection
Brand Name: ENTYVIO
International Nonproprietary Name (INN): Vedolizumab
Mechanism of Action: Not disclosed in available facts; however, vedolizumab is established as a selective antagonist of the α4β7 integrin, blocking lymphocyte adhesion and migration to the gastrointestinal tract.
Target: Not disclosed in available facts
Related Therapies: Vedolizumab is also approved for ulcerative colitis and Crohn's disease. Competitive agents in pouchitis include antimicrobials (rifaximin, vancomycin, metronidazole, ciprofloxacin, amoxicillin-clavulanate, fosfomycin) and emerging biologics such as etrasimod (phase 2, MAIA Biotechnology) and fecal microbiota transplant approaches (phase 1, MAIA Biotechnology).
First Approval: Australia (1 August 2015); European Union (15 January 2026); United States (BLA approvals BLA125476, BLA761133, BLA761359—specific dates not disclosed).
Patent Status: Not disclosed in available facts
Prevalence: Point prevalence: 1-5 / 10 000 (Europe) — source: Orphanet, validated.
Acute inflammation in the intestinal mucosa of the continent ileal reservoir (or pouch) in patients who have undergone ileostomy and restorative proctocolectomy (proctocolectomy, restorative).
ClinicalTrials.gov lists 45 registered studies for Pouchitis (AACT aggregate).
Phase breakdown: NA (16), PHASE2 (10), PHASE3 (6), PHASE4 (5), PHASE1/PHASE2 (3), EARLY_PHASE1 (2), PHASE1 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005312), Orphanet — pouchitis, NCT00061282, NCT00293553, NCT00583076, NCT00583531, NCT01202396, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Australian TGA approval
Vedolizumab (ENTYVIO) first listed on Australian Register of Therapeutic Goods.
Australian listing update
Additional PBS code listing recorded for vedolizumab in Australia.
Latest program milestone
Vedolizumab-4004 program latest milestone recorded; specific nature of milestone not disclosed.
Australian listing update
Additional PBS code listing recorded for vedolizumab in Australia.
European Union authorisation
Vedolizumab (ENTYVIO) authorised by the European Medicines Agency (EMEA/H/C/002782).
The pouchitis treatment landscape includes both established antimicrobial agents and emerging targeted biologics. Traditional first-line therapies—rifaximin, vancomycin, metronidazole, and ciprofloxacin—are small-molecule antimicrobials with limited specificity for pouchitis pathophysiology and variable efficacy; these agents are sponsored by Takeda and listed as phase 3 comparators. Vedolizumab itself (Takeda, phase 3 status in the facts) represents a mechanistically distinct approach targeting gut-homing lymphocytes. Emerging competitors include etrasimod (MAIA Biotechnology, phase 2), a selective sphingosine-1-phosphate receptor modulator, and fecal microbiota transplant (MAIA Biotechnology, phase 1), which addresses dysbiosis. Lacuna Pharma Pty Ltd is developing a combination approach (metronidazole, fosfomycin, molgramostim; phase 2), targeting both antimicrobial and immune modulation. Vedolizumab's approved status and established safety profile in inflammatory bowel disease provide competitive advantages over earlier-stage agents, though the small patient population and limited head-to-head trial data constrain definitive positioning. The competitive field remains relatively sparse, reflecting both the niche indication and the clinical challenge of pouchitis management.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE | Takeda | small_molecule | phase_3 |
| Vedolizumab | Takeda | small_molecule | phase_3 |
| METRONIDAZOLE, FOSFOMYCIN, MOLGRAMOSTIM | Lacuna Pharma Pty Ltd | small_molecule | phase_2 |
| etrasimod | MAIA Biotechnology | small_molecule | phase_2 |
| Fecal Microbiota Transplant (FMT) | MAIA Biotechnology | small_molecule | phase_1 |
| USTEKINUMAB | — | Interleukin-23 inhibitor | Phase 3 |
| ALICAFORSEN | — | Intercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 2 |
| LIRAGLUTIDE | — | Glucagon-like peptide 1 receptor agonist | Phase 2 |
| SARGRAMOSTIM | — | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Vedolizumab (ENTYVIO) holds approved status with three BLA numbers on record: BLA125476, BLA761133, and BLA761359. Specific approval dates and indication-specific approvals are not disclosed in available facts.
European Union (EMA): Vedolizumab (ENTYVIO) was authorised on 15 January 2026 under EMEA/H/C/002782 by the EMA, with Takeda Pharma A/S listed as the marketing authorisation holder.
Australia (TGA): Vedolizumab (ENTYVIO) was first listed on the Australian Register of Therapeutic Goods on 1 August 2015, with subsequent listings on 1 September 2021 and 1 October 2024. Ten PBS codes are associated with the product (10384M, 10390W, 10398G, 10415E, 12620F, 12638E, 12639F, 12644L, 12647P, 12654B), sponsored by Takeda Pharmaceuticals Australia Pty. Ltd.
China (NMPA): Vedolizumab is in clinical trials in China; NCT07398586 is registered on ClinicalTrials.gov, indicating ongoing trial activity. Regulatory approval status is not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed in available facts.
Vedolizumab is approved for the treatment of pouchitis, an inflammatory condition affecting the surgically created ileal pouch in patients who have undergone total proctocolectomy. It is also approved for ulcerative colitis and Crohn's disease.
Yes, vedolizumab has completed clinical development and is approved in multiple jurisdictions including Australia (since 2015), the European Union (authorised 15 January 2026), and the United States (BLA approvals on record).
Vedolizumab is a selective integrin antagonist that blocks α4β7 integrin, preventing lymphocyte adhesion and migration to the gastrointestinal tract, thereby reducing gut inflammation.
Vedolizumab (ENTYVIO) is manufactured and sponsored by Takeda Pharmaceuticals, with regional subsidiaries including Takeda Pharma A/S (EU) and Takeda Pharmaceuticals Australia Pty. Ltd.
Vedolizumab is administered via injection.
The pivotal trial NCT02790138 is associated with the Vedolizumab-4004 program; detailed trial results are not yet disclosed in available facts.
Vedolizumab is a selective α4β7 integrin antagonist that blocks lymphocyte homing to the gastrointestinal tract; specific molecular targets are not disclosed in available facts.
Competing treatments include antimicrobials (rifaximin, vancomycin, metronidazole, ciprofloxacin), emerging biologics such as etrasimod (phase 2), and fecal microbiota transplant approaches (phase 1).
Vedolizumab was first listed in Australia on 1 August 2015; US and EU approval dates are not specifically disclosed, though EU authorisation occurred on 15 January 2026.
Yes, vedolizumab (ENTYVIO) was authorised by the European Medicines Agency on 15 January 2026 under EMEA/H/C/002782.
Yes, vedolizumab holds approved status in the United States with three BLA numbers on record (BLA125476, BLA761133, BLA761359); specific approval dates are not disclosed.
The patient population includes individuals who have undergone ileal pouch-anal anastomosis surgery, typically following total proctocolectomy for ulcerative colitis or familial adenomatous polyposis, and who experience pouchitis symptoms.
Vedolizumab-4004 has completed clinical development and achieved approved status in multiple jurisdictions; no further development phases are indicated.
No partner is disclosed for the Vedolizumab-4004 program; development is sponsored solely by Takeda Pharmaceuticals.
Vedolizumab is classified as a small-molecule integrin antagonist administered via injection.
The pivotal trial NCT02790138 is associated with the completed Vedolizumab-4004 program. A separate trial (NCT07398586) is registered in China for vedolizumab, indicating ongoing clinical trial activity in that jurisdiction.
Vedolizumab Placebo → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Takeda's approval of vedolizumab in pouchitis represents a targeted label expansion strategy, leveraging existing clinical and regulatory infrastructure to address a high-need but smaller patient population. This approach maximizes return on the vedolizumab platform investment without requiring de novo development programs.
Competitive Implications: Vedolizumab's approved status and mechanistic differentiation (integrin antagonism) position it ahead of earlier-stage competitors such as etrasimod (phase 2) and FMT approaches (phase 1). However, the reliance on antimicrobial comparators (rifaximin, vancomycin, metronidazole) in current clinical practice suggests that head-to-head efficacy and cost-effectiveness data will be critical for market penetration, particularly in health systems with established antimicrobial protocols.
Future Catalysts: Publication of pivotal trial data from NCT02790138 will be essential for clinical adoption and reimbursement discussions. Real-world evidence studies comparing vedolizumab to standard antimicrobial regimens may further support market positioning. Regulatory approvals in additional jurisdictions (Japan, China) could expand the addressable patient population, though pouchitis prevalence is lower in Asian populations.
Expected Milestones: No specific next milestones are disclosed in available facts. Anticipated catalysts include peer-reviewed publication of trial results, potential label expansions to related indications (e.g., chronic pouchitis refractory to antimicrobials), and real-world effectiveness data from post-marketing surveillance.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.